Wenchao Zhang1, Jiawei Li1, Ran Li2, Ying Zhang2, Mingyong Han3, Wei Ma4. 1. Department of Epidemiology, School of Public Health, Shandong University, Jinan, Shandong, China. 2. Cancer Therapy and Research Center, Shandong Provincial Hospital affiliated to Shandong University, Jinan, Shandong, China. 3. Cancer Therapy and Research Center, Shandong Provincial Hospital affiliated to Shandong University, Jinan, Shandong, China. Electronic address: hanmingyong@sina.com. 4. Department of Epidemiology, School of Public Health, Shandong University, Jinan, Shandong, China. Electronic address: weima@sdu.edu.cn.
Abstract
PURPOSE: This meta-analysis was conducted to investigate the efficacy and safety of 125I brachytherapy for locally advanced non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Trials comparing 125I brachytherapy with chemotherapy in NSCLC were identified. Meta-analysis was performed to obtain pooled risk ratios for an overall response rate (ORR), disease control rate (DCR) and complications, and pooled hazard ratio for overall survival (OS). RESULTS: Fifteen studies including 1188 cases were included. The pooled result indicated that there were significant differences in ORR, DCR, and OS between 125I brachytherapy combined with chemotherapy and chemotherapy alone, but no statistic differences in gastrointestinal symptoms, leukopenia, myelosuppression, and hemoglobin reduction. Patients treated with 125I brachytherapy combined with chemotherapy have a higher relative risk of pneumothorax, bloody sputum, and pneumorrhagia compared with chemotherapy alone. Seeds migration only occurred in the group treated with 125I brachytherapy. There were significant differences in ORR, DCR, and myelosuppression between 125I brachytherapy alone and chemotherapy. CONCLUSIONS: 125I brachytherapy combined with chemotherapy can significantly enhance the clinical efficacy and improve the OS of patients with advanced NSCLC without increasing the incidence of complications of chemotherapy. 125I brachytherapy alone can significantly enhance the clinical efficacy and reduce the incidence of myelosuppression compared with chemotherapy. However, 125I brachytherapy may cause lung injury. Large sample and higher-quality randomized controlled trials are needed to confirm the pooled results of complications.
PURPOSE: This meta-analysis was conducted to investigate the efficacy and safety of 125I brachytherapy for locally advanced non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Trials comparing 125I brachytherapy with chemotherapy in NSCLC were identified. Meta-analysis was performed to obtain pooled risk ratios for an overall response rate (ORR), disease control rate (DCR) and complications, and pooled hazard ratio for overall survival (OS). RESULTS: Fifteen studies including 1188 cases were included. The pooled result indicated that there were significant differences in ORR, DCR, and OS between 125I brachytherapy combined with chemotherapy and chemotherapy alone, but no statistic differences in gastrointestinal symptoms, leukopenia, myelosuppression, and hemoglobin reduction. Patients treated with 125I brachytherapy combined with chemotherapy have a higher relative risk of pneumothorax, bloody sputum, and pneumorrhagia compared with chemotherapy alone. Seeds migration only occurred in the group treated with 125I brachytherapy. There were significant differences in ORR, DCR, and myelosuppression between 125I brachytherapy alone and chemotherapy. CONCLUSIONS: 125I brachytherapy combined with chemotherapy can significantly enhance the clinical efficacy and improve the OS of patients with advanced NSCLC without increasing the incidence of complications of chemotherapy. 125I brachytherapy alone can significantly enhance the clinical efficacy and reduce the incidence of myelosuppression compared with chemotherapy. However, 125I brachytherapy may cause lung injury. Large sample and higher-quality randomized controlled trials are needed to confirm the pooled results of complications.
Authors: Aik Hao Ng; Mohammed S Alqahtani; Layal K Jambi; Sarah L Bugby; John E Lees; Alan C Perkins Journal: Br J Radiol Date: 2019-04-24 Impact factor: 3.039